Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
NCT03109236Phase 3Unknown
- Sponsor
- National University Hospital
- Start
- Aug 2017
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Liver cirrhosis (LC) (2 arms), sponsored by National University Hospital. Primary endpoints: Improvement of Fibrosis Staging (Ishak) at 3 months, Improvement of liver fibrosis on MRE (magnetic resonance elastography) at 6 months and 2 more. Status: unknown.
02
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT03109236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109236.